Pharmacogenetics Pain Management and Psychotropic Panel

Test Code: MPG03
Turnaround time: 10 days
CPT Codes: 81225 x1, 81226 x1, 81227 x1, 81230 x1, 81231 x1, 81240 x1, 81241 x1

Condition Description

Pharmacogenomics (or pharmacogenetics), abbreviated PGx, is the study of how genes affect a person’s response to certain drugs. PGx testing uses genetic information to predict how individual patients will metabolize some prescription medications. This prediction allows an effective dose to be tailored to a person’s genetic makeup, helping to prevent adverse drug reactions. Pharmacogenetics Extended Test targets variants to genotype for various haplotypes among the following 10 genes.

Genes and Alleles Tested:
- **ANKK1/DRD2** DRD2:Taq1A;
- **COMT** NM_000754.3:c.472G>A(p.V158M); rs4680
- **CYP3A4** *1B, *1C, *17, *22;
- **OPRM1** NM_000914.3:c.118A>G(p.N40D); rs1799971

Note that “*” (read as “star”) denotes the common name of a haplotype (or combination of alleles within a gene on the same chromosome).

Indications

Individuals who meet the defined clinical criteria for being prescribed specific drugs for psychotropic medications and pain management.

Methodology

The test uses custom manufactured TaqMan® drug metabolism and SNP genotyping assays in 384-well format that are run on the QuantStudio™ 6 Flex platform. The complete test consists of two components: SNP genotyping and copy number quantification. The SNP genotyping component consists of 64 TaqMan® SNP Assays for 63 loci, which include single base and short insertion/deletion polymorphisms. The copy number component consists of one TaqMan® Copy Number assay for the CYP2D6 gene.

Specimen Requirements

Related Tests

Pharmacogenetics Expanded Panel (MPG01)